These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 26307947)

  • 1. Multimodal approach to explore the pathogenicity of BARD1, ARG 658 CYS, and ILE 738 VAL mutants.
    Choudhary RK; Vikrant ; Siddiqui QM; Thapa PS; Raikundalia S; Gadewal N; Kumar NS; Hosur MV; Varma AK
    J Biomol Struct Dyn; 2016 Jul; 34(7):1533-44. PubMed ID: 26307947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis to stabilize the domain motion of BARD1-ARD BRCT by CstF50.
    Choudhary RK; Siddiqui MQ; Thapa PS; Gadewal N; Nachimuthu SK; Varma AK
    Sci Rep; 2017 Jun; 7(1):3849. PubMed ID: 28634376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thermodynamic study of the BRCT domain of BARD1 and its interaction with the -pSER-X-X-Phe- motif-containing BRIP1 peptide.
    Thanassoulas A; Nomikos M; Theodoridou M; Yannoukakos D; Mastellos D; Nounesis G
    Biochim Biophys Acta; 2010 Sep; 1804(9):1908-16. PubMed ID: 20451671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal structure of the BARD1 BRCT domains.
    Birrane G; Varma AK; Soni A; Ladias JA
    Biochemistry; 2007 Jul; 46(26):7706-12. PubMed ID: 17550235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thermal and chemical denaturation of the BRCT functional module of human 53BP1.
    Thanassoulas A; Nomikos M; Theodoridou M; Stavros P; Mastellos D; Nounesis G
    Int J Biol Macromol; 2011 Oct; 49(3):297-304. PubMed ID: 21600917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biophysical evaluation to categorize pathogenicity of cancer-predisposing mutations identified in the BARD1 BRCT domain.
    Choudhary RK; Siddiqui MQ; Gadewal N; Kumar NS; Kuligina ES; Varma AK
    RSC Adv; 2018 Sep; 8(59):34056-34068. PubMed ID: 35548793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The BARD1 C-terminal domain structure and interactions with polyadenylation factor CstF-50.
    Edwards RA; Lee MS; Tsutakawa SE; Williams RS; Nazeer I; Kleiman FE; Tainer JA; Glover JN
    Biochemistry; 2008 Nov; 47(44):11446-56. PubMed ID: 18842000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural requirements for the BARD1 tumor suppressor in chromosomal stability and homology-directed DNA repair.
    Laufer M; Nandula SV; Modi AP; Wang S; Jasin M; Murty VV; Ludwig T; Baer R
    J Biol Chem; 2007 Nov; 282(47):34325-33. PubMed ID: 17848578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative feedback loop of BRCA1-BARD1 ubiquitin ligase on estrogen receptor alpha stability and activity antagonized by cancer-associated isoform of BARD1.
    Dizin E; Irminger-Finger I
    Int J Biochem Cell Biol; 2010 May; 42(5):693-700. PubMed ID: 20060929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 DNA-binding activity is stimulated by BARD1.
    Simons AM; Horwitz AA; Starita LM; Griffin K; Williams RS; Glover JN; Parvin JD
    Cancer Res; 2006 Feb; 66(4):2012-8. PubMed ID: 16489000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SIRT2 promotes BRCA1-BARD1 heterodimerization through deacetylation.
    Minten EV; Kapoor-Vazirani P; Li C; Zhang H; Balakrishnan K; Yu DS
    Cell Rep; 2021 Mar; 34(13):108921. PubMed ID: 33789098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-engineering a split-GFP reassembly screen to examine RING-domain interactions between BARD1 and BRCA1 mutants observed in cancer patients.
    Sarkar M; Magliery TJ
    Mol Biosyst; 2008 Jun; 4(6):599-605. PubMed ID: 18493658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural insight into BRCA1-BARD1 complex recruitment to damaged chromatin.
    Dai L; Dai Y; Han J; Huang Y; Wang L; Huang J; Zhou Z
    Mol Cell; 2021 Jul; 81(13):2765-2777.e6. PubMed ID: 34102105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs.
    Atipairin A; Canyuk B; Ratanaphan A
    Breast Cancer Res Treat; 2011 Feb; 126(1):203-9. PubMed ID: 20878461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico investigation on the mutational analysis of BRCA1-BARD1 RING domains and its effect on nucleosome recognition and ubiquitination.
    Sarma H; Kiewhuo K; Jamir E; Sastry GN
    Biophys Chem; 2023 Sep; 300():107070. PubMed ID: 37339533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential requirement for BRCA1-BARD1 E3 ubiquitin ligase activity in DNA damage repair and meiosis in the Caenorhabditis elegans germ line.
    Li Q; Kaur A; Okada K; McKenney RJ; Engebrecht J
    PLoS Genet; 2023 Jan; 19(1):e1010457. PubMed ID: 36716349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation.
    Li M; Yu X
    Cancer Cell; 2013 May; 23(5):693-704. PubMed ID: 23680151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular dynamics simulations reveal the effect of mutations in the RING domains of BRCA1-BARD1 complex and its relevance to the prognosis of breast cancer.
    Kiewhuo K; Priyadarsinee L; Sarma H; Sastry GN
    J Biomol Struct Dyn; 2023; 41(22):12734-12752. PubMed ID: 36775657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The BRCT Domains of the BRCA1 and BARD1 Tumor Suppressors Differentially Regulate Homology-Directed Repair and Stalled Fork Protection.
    Billing D; Horiguchi M; Wu-Baer F; Taglialatela A; Leuzzi G; Nanez SA; Jiang W; Zha S; Szabolcs M; Lin CS; Ciccia A; Baer R
    Mol Cell; 2018 Oct; 72(1):127-139.e8. PubMed ID: 30244837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase.
    Eakin CM; Maccoss MJ; Finney GL; Klevit RE
    Proc Natl Acad Sci U S A; 2007 Apr; 104(14):5794-9. PubMed ID: 17392432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.